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Abstract
Background: Metastasis in breast cancer is a vital concern in treatment because most women
with primary breast cancer have micrometastases to distant sites at diagnosis. As a member of the
inhibitor of apoptosis protein (IAP) family, survivin has been proposed as an attractive target for
new anticancer interventions. In this study, we investigated the role of the plasmid encoding the
phosphorylation-defective mouse survivin threonine 34→alanine mutant (Msurvivin T34A plasmid)
in suppressing both murine primary breast carcinomas and pulmonary metastases.
Methods: In vitro study, induction of apoptosis by Msurvivin T34A plasmid complexed with
cationic liposome (DOTAP/Chol) was examined by PI staining fluorescence microscopy and flow
cytometric analysis. The anti-tumor and anti-metastases activity of Msurvivin T34A plasmid
complexed with cationic liposome (DOTAP/Chol) was evaluated in female BALB/c mice bearing
4T1 s.c. tumors. Mice were treated twice weekly with i.v. administration of Msurvivin T34A plasmid
complexed with cationic liposome (DOTAP/Chol), PORF-9 null plasmid complexed with cationic
liposome (DOTAP/Chol), 0.9% NaCl solution for 4 weeks. Tumor volume was observed. After
sacrificed, tumor net weight was measured and Lung metastatic nodules of each group were
counted. Assessment of apoptotic cells by TUNEL assay was conducted in tumor tissue.
Microvessel density within tumor tissue was determined by CD31 immunohistochemistry.
Alginate-encapsulated tumor cells test was conducted to evaluate the effect on angiogenesis. By
experiment of cytotoxicity T lymphocytes, we test whether Msurvivin T34A plasmid complexed
with cationic liposome (DOTAP/Chol) can induce specific cell immune response.
Results: Administration of Msurvivin T34A plasmid complexed with cationic liposome (DOTAP/
Chol) resulted in significant inhibition in the growth and metastases of 4T1 tumor model. These
anti-tumor and anti-metastases responses were associated with triggering the apoptosis of tumor
cells directly, inhibiting angiogenesis and inducing specific cellular immune response.
Conclusion: The present findings suggest that the Msurvivin T34A plasmid complexed with
cationic liposome may provide an effective approach to inhibit the growth and metastases of a
highly metastatic mouse breast cancer model with minimal side effects.
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Background
Epidemiologic studies indicate 180,510 new cases of
breast cancer will be diagnosed and 40,910 will die of
breast carcinoma only in the united states in 2007.
Recently breast carcinoma has been the most common
malignancy in women and is second only to lung cancer
as a cause of cancer death[1]. Although breast cancer mor-
tality appears to be declining due to a benefit from early
detection and more effective treatment, metastasis after
surgical resection plays an important role in the failure of
therapy and the death of patients. In view of these, more
effective strategies need to be developed. Breast tumours
mainly metastasize to the lungs and bones. A murine
mammary carcinoma cell 4T1 has a highly metastatic
characteristic at an early stage, which is similar to the
human breast cancer and make it an excellent animal
model to evaluate the effects of drugs on breast tumor
metastases as well as growth [2,3].
As a member of the inhibitory apoptotic protein family,
survivin is a 16.5 kda antiapoptotic protein. By targeting
caspase 9 via interaction with cofactor molecules, survivin
tends to hinder mitochondrial-dependent apoptosis[4].
Because of its role in regulation of the balance between
programmed cell death and cell proliferation during cell
cycle, survivin is vital for cancer cell survival, which makes
it an attractive target for new anticancer interventions [4-
6]. The protein is strongly expressed in the most common
human neoplasms, embryonic and fetal organs but is gen-
erally undetectable in differentiated normal tissues with
the exception of thymus, basal colonic epithelium and
endothelial cells [7-11]. Moreover, the level of survivin
protein appears to be involved in tumour cell resistance to
ionizing radiation[12] and some anticancer
agents[13,14]. Meanwhile, previous studies have demon-
strated that the overexpression of survivin correlates with
poor survival of patients and poor prognosis[15].
Recently, considerable efforts including antisense[16],
ribozymes[17], RNAi-mediated[18,19] survivin knock-
down, survivin-directed vaccines[20] or dominant nega-
tive mutants[16,21] have been made to counteract sur-
vivin in tumor cells in order to inhabit tumor growth
potential and enhance tumor cell response to apoptosis-
inducing anti-cancer agents. Results from studies exploit-
ing different strategies to interfere with survivin expres-
sion and function provided direct and convincing
evidence that targeting survivin is a promising approach
for cancer therapy. It was suggested that dominant nega-
tive mutants including survivin Thr34→Ala, survivin
Cys84→Ala could reduce tumor cell proliferative poten-
tial and lead to caspase-dependent apoptosis in
melanoma cell lines[16,21]. The results of several previ-
ous basic studies and phase I trials based on the adminis-
tration of survivin-directed Cytotoxic T lymphocytes have
been completed and proved to be an effective and safe
method to move on to clinical phase 2 studies[20,22].
However, no findings that Msurvivin T34A mutant can
deal with highly metastatic breast carcinoma have been
reported. Compared with intratumor injection reported
before, intravenous injection we used can control
micrometastases throughout the body and can be
extended to the clinical application better. In this study,
we focus on this main under-explored question: to test
whether Msurvivin T34A plasmid complexed with cati-
onic liposome (DOTAP/CHOL) may provide good anti-
tumor effect to murine metastatic mammary carcinoma
and inhibit experimental tumor metastases by injection
through tail vein.
Methods
Cell and cell cultures
The 4T1 mouse mammary carcinoma cells and the murine
endothelial cells(MS1) (obtained from American Type
Culture Collection, ATCC, Rockville MD) were cultured in
Dulbecco's modified Eagle medium (DMEM) (Gibco
BRL, Grand Island, N.Y.) supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 100 μg/ml amikacin
and were maintained in humidified chamber at 37°C in
5% CO2 atmosphere.
Expression vector
The recombinant plasmids carrying PORF-9-Msurvivin
T34A or PORF-9 null were purchased from Invivogen Cor-
poration. The recombinant plasmid was confirmed by
restriction endonuclease analysis, PCR and DNA sequence
analysis (data not shown). The plasmid PORF-9 null with-
out mutant survivin gene was used as a control in the
experiment.
The plasmid DNA preparation
The plasmid was prepared using Endofree Plasmid Giga
kit (Qiagen, Chatsworth, CA). Endotoxin levels of the
plasmid DNA prepared were determined by Tachypleus
Amebocyte Lysate (TAL). No genomic DNA, small DNA
fragments, or RNA were detected in the DNA prepared
and the OD260/280 ratios of the plasmid DNA prepared
were between 1.8–2.0. The DNA was eventually dissolved
in sterile endotoxin free water and stored at -20°C before
use.
Liposome preparation
DOTAP:chol liposome was prepared using the procedure
described previously [23]. Briefly, the cationic lipid
DOTAP was mixed with the neutral lipid Chol at equimo-
lar concentrations. The mixed lipids were dissolved in
chloroform in a 100 ml-round-bottomed flask. Then, the
clear solution was rotated on a Buchi rotary evaporator at
30°C for 30 min to make a thin film, the flask containing
the thin lipid film was dried under vacuum for 15 min.Journal of Experimental & Clinical Cancer Research 2008, 27:46 http://www.jeccr.com/content/27/1/46
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The film was hydrated in 5% dextrose in water (D5W) to
give a final concentration of 7 mM DOTAP and 7 mM
chol, referred to as 7 mM DOTAP:chol. The hydrated lipid
film was rotated in a water bath at 50°C for 45 min and
then 35°C for 10 min. The mixture was allowed to stand
in the parafilm-covered flask at room temperature over-
night, after which the mixture was sonicated at low fre-
quency for 5 min at 50°C, transferred to a tube, and
heated for 10 min at 50°C. The mixture was sequentially
extruded through Millipore (Billerica, MA) polycarbonate
membrane of decreasing size: 0.2 μm for 5 times and 0.1
μm for 3 times using syringes. Liposome were stored
under argon gas at 4°C. DOTAP was purchased from
Avanti Polar Lipids (Alabaster, AL); and highly purified
Chol was purchased from Sigma (St. Louis, MO).
Apoptotic detection in vitro
Cellular transfection
The recombinant pcDNA3.1 plasmid encoding for the
green fluorescent protein was used to find the ideal plas-
mid:liposome ratio (μg/μg) for the most efficient gene
delivery. A maximum expression was obtained when 2μg
plasmid/6μg liposome was used (data not shown).
For transfection, 2 × 105 cells (including 4T1 cells or MS1
cells) were plated into 6-well plates (10 cm2 growth area)
and incubated overnight in DMEM to 60% to 70% conflu-
ence.2 μg DNA (Msurvivin T34A plasmid or PORF-9 null
plasmid) with 6 μL liposome was dissolved in 500 μL of
serum-free DMEM without antibiotics for 30 minutes at
25°C and added directly to cell cultures. Cells were then
incubated for 6 hours at 37°C, after which, the media
were replaced with fresh serum-supplemented media with
antibiotics.48 hours later, cells were harvested to be used
to apoptotic analysis as described below.
Morphological analysis
After transfection, cells were resuspended in hypotonic
propidium iodide solution containing 50 micro g PI/ml
in 0.1% sodium citrate plus 0.1% Triton X-100 and exam-
ined by fluorescence microscopy.
The quantitative assessment of apoptosis
Harvested cells were stained with 1 ml hypotonic fluoro-
chrome solution containing 50 micro g/ml propidium
iodide in 0.1% sodium citrate plus 0.1% Triton X-100.
Then flow cytometric analysis could be performed to
identify apoptotic cells or sub-G1 cells and to measure the
percentage of sub-G1 cells by the use of a flow cytometer
(ESP Elite; Coulter). Apoptotic cells has a less DNA con-
tent than that of G1 cells in the cell cycle distribution and
the results was estimated with list mode software.
Animal experiments
Female BALB/c mice and KM mice of 6 to 8 weeks old were
purchased from experimental animal center of Sichuan
University (Chengdu, Sichuan province, China) and were
housed in our animal research facility. Mice were kept in
groups of five per cage and fed with clean food and water.
The animals were acclimatized for 1 week before use and
maintained throughout at standard conditions: 24 ± 2°C
temperature, 50 ± 10% relative humidity.
Female BALB/C mice were challenged s.c with 1 × 105 4T1
mouse breast tumor cells in the right flank on day 0. Pri-
mary tumors were palpable on day 7–9 and had a mean
diameter of 3 mm on day 9. The tumor-bearing mice were
randomly assigned into the following three groups and
received the corresponding treatment: (a) mice received
25  μg Msurvivin T34A plasmid/75 μg liposome com-
plexes (volume = 200 μl), (b) mice received 25 μg PORF-
9 null plasmid/75 μg liposome complexes (volume =
200μl), and (c) mice received 200 μl 0.9% NaCl solution
(NS). Each group has 10 mice. Half an hour before tail
vein injection, DNA:liposome complexes were pre-
pared.25 μg DNA was diluted in D5W (dextrose 5% in
water), and 75 μg liposome were diluted in D5W to pro-
duce 1:3 ratio of DNA (μg): liposome (μg). Equal volumes
of both the DNA solution and the liposome solution were
mixed gently and incubated at room temperature for 30
min. The systemic therapy started on day 10 and was
repeated twice a week for the total of 8 times. The mice
were bled via the tail vein at weekly intervals to collect
serum. On day 38, all mice from each group were sacri-
ficed. Tumor net weight of each mouse was measured.
Tumor growth was evaluated by measurement of tumor
diameters every 3 or 4 days and the tumor volume was cal-
culated as length × width2 × 0.52. All of the data are repre-
sented as means ± SE.
Autopsy was performed to determine the number and
diameter of the metastatic nodules of lung. Organs (lung,
liver, kidney, heart and spleen) and tumors from sacri-
ficed mice were removed, fixed in the 4% formaldehyde
solution for histologic analysis.
Histologic analysis
Primary tumors were fixed in 4% paraformaldehyde in
PBS, embedded in paraffin and cut into 3–5 μm sections.
Then the sections were stained with hematoxylin and
eosin (H&E). The presence of apoptotic cells within the
tumor sections was evaluated by the TUNEL (terminal
deoxynucleotidyltransferase-mediated dUTP nick-end
labeling) technique using the DeadEnd Fluorometric
TUNEL System (Promega, Madison, WI) following the
manufacturer's protocol. Percent apoptosis was deter-
mined by counting the number of apoptotic cells andJournal of Experimental & Clinical Cancer Research 2008, 27:46 http://www.jeccr.com/content/27/1/46
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dividing by the total number of cells in the field (5 high
power fields/slide).
Immunohistochemistry analyses of microvessel expres-
sion were done with goat anti-mouse CD31 antibody
(Santa Cruz Biotechnology) using the labeled streptavi-
din-biotin method. That is to say, Sections were deparaffi-
nized in xylol and rehydrated in graded alcohol series.
Antigen retrieval was carried out by autoclaving sections
in retrieval buffer (10 mM pH 6.0 EDTA citrate buffer) for
3 min in saturated steam after up-pressure gaining
(126°C, 1.6 bars, 23 psi). Endogenous peroxidase activity
was blocked by incubation in 3% hydrogen peroxide at
room temperature free of light for 20 min. Nonspecific
binding of reagents was quenched by incubation of sec-
tions for 20 min in 5% normal rabbit serum. Sections
were then incubated with goat anti-mouse CD31 (dilu-
tion 1/200) antibodies overnight at 4°C, followed by
incubating with biotinylated rabbit anti-goat IgG and
then streptavidin-biotin-horseradish peroxidase complex
at 37°C for 1 hour severally. Negative control was
included with each run by substituting the primary anti-
body with non-immune rabbit serum. Cellular nuclei
were counterstained with ameliorative Gill's hematoxylin.
CD31 immunohistochemical evaluation
According to the method of Weidner et al. [24], the quan-
tification of microvessel density (MVD) was assessed. The
sections were firstly screened at low magnifications (×40
and ×100) to identify the most vascular area of the tumor
called hot spot. Within the hot spot area, the stained
microvessel were counted in a single high-power (×400)
field. MVD was expressed as the number of microvessel/
field. Any CD31-stained endothelial cells or endothelial
cell clusters that were clearly separate from adjacent
microvessel, tumor cells, or connective tissue elements
were considered a single countable microvessel.
Alginate-encapsulated tumor cells test
As a specific tumor angiogenesis model in vivo, the algi-
nate-encapsulated tumor cells test was conducted in order
to investigate whether or not the use of Msurvivin T34A
plasmid would significantly reduce the angiogenesis at
the alginate implant. All BALB/c female mice were injected
s.c. with 0.1 ml of alginate beads containing 1 × 105 4T1
cells into the upper third of the back. The next day, mice
were randomly assigned into one of the following three
groups (n = 5): (a) mice received 25 μg Msurvivin T34A
plasmid/75 μg liposome complexes (volume = 200 μl),
(b) mice received 25 μg PORF-9 null plasmid/75 μg lipo-
some complexes (volume = 200 μl), and (c) mice received
200 μl 0.9% NaCl solution (NS). Treatment of Msurvivin
T34A plasmid (twice/week) started on the same day. Two
weeks later, 200 μl of 1% FITC-dextran solution (100 mg/
kg) was injected i.v. into the tail vein of mice. All the algi-
nate implants were removed 20 min after FITC-dextran
injection as soon as possible. Image of the alginate
implants was taken by using SPOT FIEX camera. Alginate
beads were transferred to tubes containing 2 ml of saline.
The tubes were mixed by a vortex for 20 s and centrifuged
(3 min; 1000 × g). Finally the fluorescence of the superna-
tant was measured to quantify blood vessel formation.
Cytotoxic T lymphocytes assay
According to the methods described in [25,26], mononu-
clear cells of spleen were harvested and depleted of red
cells with ammonium chloride and passed through nylon
wool after the mice were sacrificed. Effector cells, T cells of
spleen, were prepared. Target cells 4T1 were labeled with
300 mci of Na2 
51CrO4 for 2 h, washed, and dispensed into
the wells of 96-well plates. Different number of the effec-
tor cells were added in duplicates to generate different E:T
ratios. The radioactivity released into supernatants was
measured in a scintillation counter.
Toxicity assessment
In order to evaluate the potential side effects in the Msur-
vivin T34A plasmid:lipo complexes-treated mice, they
were continuously observed for relevant indexes such as
weight loss, ruffled fur, diarrhea, anorexia, skin ulceration
and toxic death. After mice were sacrificed, various organs
(heart, liver, spleen, lung, kidney, brain, etc.) were har-
vested and fixed in 4% paraformaldehyde in PBS. These
tissues were then sectioned, stained with H&E and
observed by two pathologists in a double- blinded man-
ner. In order to evaluate hematologic toxicity, blood test
was conducted. In addition, the acute toxicity was also
assessed. Some KM mice about 6–8 weeks old were ran-
domly assigned to the following three groups and
received the corresponding treatment: (a) mice received
25  μg Msurvivin T34A plasmid/75 μg liposome com-
plexes (volume = 200 μl), (b) mice received 25 μg PORF-
9 null plasmid/75 μg liposome complexes (volume = 200
μl), and (c) mice received 200 μl of 0.9% NaCl solution
(NS). Every group has 6 mice. Blood samples were col-
lected from the retro-orbital vein 48 hours after the injec-
tion. The levels of serum ALT and AST were determined
with an automatic multifunction-biochemical analyzer.
Statistical analysis
Statistical analysis of the differences in tumor volume,
tumor net weight, animal weight, percent apoptosis,
microvessel density and the level of serum transaminase
were performed using one-way analysis of variance
(ANOVA). Because distribution of metastatic tumors in
the lungs is not normal, the data have to be presented as
medians, and statistical analysis of the differences in
metastasis formation was analyzed using the Mann-Whit-
ney test. A P < 0.05 was considered statistically significant.Journal of Experimental & Clinical Cancer Research 2008, 27:46 http://www.jeccr.com/content/27/1/46
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Results
Apoptotic morphological observation
Treatment with Msurvivin T34A plasmid of tumor cells
4T1 contributed to morphological changes characteristic
for apoptosis: brightly red-fluorescent nuclei (fragmented
or intact) displayed by fluorescence microscopy of PI-
stained nuclei, reduction of cell volume, condensation of
nuclear chromatin, nuclear fragmentation and apoptotic
bodies. By contrast, the other groups (including the
untransfected and the transfected with PORF-9 null plas-
mid) did not demonstrate obvious changes (Figure 1).
Flow cytometry analysis
The quantitative assessment of sub-G1 cells by flow
cytometry was used to estimate the number of apoptotic
cells.4T1 cells treated with Msurvivin T34A plasmid for 48
hr. have a striking sub-G1 peak compared with the other
groups (including the untransfected and the transfected
with PORF-9 null plasmid), with 43%, 2% and 8.6% sub-
G1 cells (apoptotic cells), respectively, as assessed by flow
cytometry (Figure 2).
Anti-tumor effect of Msurvivin T34A plasmid in vivo
In order to examine the applicability of Msurvivin T34A
plasmid complexed with cationic liposome(DOTAP/
Chol)in vivo system, we established the murine metastatic
breast tumor model by subcutaneous inoculation of 1 ×
105 tumor cells.10 days later, mice were randomized to
receive administration of Msurvivin T34A plasmid, PORF-
9 null plasmid and normal saline separately. Tumor vol-
ume presented in were monitored every 3 to 4 days (Fig-
ure 3A). At the termination of the experiment, all the
animals were sacrificed and the tumor weight of each
mouse from the three groups were measured (Figure 3B).
It is obvious that the treatment with Msurvivin T34A plas-
mid resulted in primary tumor growth regression of 73%
and 57%, respectively, compared with NS and PORF-9
null plasmid groups(P < 0.05). The corresponding results
were also found in the tumor weight. We observed the
average weight of the tumors in Msurvivin T34A plasmid
treated group was reduced by 68% and 46% when com-
pared with the NS and PORF-9 null plasmid groups(P <
0.01). All the data showed that the Msurvivin T34A plas-
mid has a significant influence on the supression of tumor
growth.
Msurvivin T34A plasmid inhibits the metastasis of 4T1 
fromthe primary tumor site to the lungs in vivo
Since the 4T1 breast tumor cells have been confirmed to
have the large potential to metastasize to the lung, liver,
brain and so on within 2 weeks [27-29], the therapeutic
efficacy against metastases was evaluated at the day 38,
when mice were sacrificed and lungs, livers, hearts,
spleens and kidneys were carefully examined. Moreover,
the tumor nodules on the lungs were counted, for some
studies have showed the metastases to the lungs can rep-
resent the extent of the cell spreading throughout the mice
[3,30]. From the results of examination, we found that the
NS group had a median of 37 metastases/lungs(range,
22–45 metastases), and the median of PORF-9 null plas-
mid group is 34 metastases/lungs(range, 19–46 metas-
tases), whereas mice treated with Msurvivin T34A plasmid
had a median of 5 metastases/lungs(range,0–9 metas-
tases), respectively. To our delight, 4 of 10 mice had no
visible lung metastases in the group treated with Msur-
vivin T34A plasmid (Table 1). The results of H&E staining
of lungs conformed to the visible observation (Figure 4A).
These results indicate that Msurvivin T34A plasmid has a
potent ability to stimulate anti-tumor and anti-metastases
activity in these mice with established 4T1 breast tumor.
Fluorescence microscopic appearance of propidium iodide (PI)-stained nuclei Figure 1
Fluorescence microscopic appearance of propidium iodide (PI)-stained nuclei. 4T1 cells were treated with Msur-
vivin T34A plasmid(2 μg per well)for 48 hr. (a) untransfected (b)transfected with PORF-9 null plasmid(c)transfected with Msur-
vivin T34A plasmid, reduction of cell volume, condensation of nuclear, nuclear fragmentation, and apoptotic bodies.Journal of Experimental & Clinical Cancer Research 2008, 27:46 http://www.jeccr.com/content/27/1/46
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Inhibition of tumor-induced angiogenesis (CD31) and 
increase of apoptosis (TUNEL)
Tumor sections of each group were stained with anti-
CD31 antibody (Figure 5A) and TUNEL reagent (Figure
6A) in order to evaluate microvessel density (MVD) and
apoptosis rate as described above. Tumor of the control
groups(including NS and PORF-9 null plasmid groups)
demonstrated high microvessel density while those of the
Msurvivin T34A plasmid group had decreased values(P <
0.05) (Figure 5B). Meanwhile we can find a large area of
necrosis in the section of Msurvivin T34A plasmid treated
group. There was much more apoptotic cells seen in those
from Msurvivin T34A plasmid treated group than in the
control groups. Furthermore, tumors from animals that
received Msurvivin T34A plasmid tended to display the
highest apoptotic indices(P < 0.05) (Figure 6B). These
data can suggest mouse Msurvivin T34A plasmid can
cause the inhibition of angiogenesis and directly increase
apoptosis of tumor cells, which play an important role in
the treatment of breast carcinoma.
Apoptosis induction of Msurvivin T34A plasmid on 
murineendothelial cells (MS1) in vitro
In order to investigate the mechanism by which the Msur-
vivin T34A plasmid affected angiogenesis, the impact of
Msurvivin T34A plasmid on murine endothelial cells
(MS1) was tested after the transfection as described above.
The characteristic changes such as a brightly red-fluores-
cent condensed nuclei(intact or fragmented), reduction of
cell volume and apoptotic bodies can be observed in the
Msurvivin T34A plasmid treated group after the PI-stain-
ing(data not shown). The numbers of apoptotic cells were
quantitatively estimated by observing sub-G1 cells by the
flow cytometry. The results displayed that there were a
much lager amount of apoptotic cells in the Msurvivin
T34A plasmid treated group than in the others(including
the PORF-9 null plasmid and the PBS treated groups)(Fig-
ure 7)
Alginate-encapsulated tumor cells test
Alginate can not only provide the tumor cells and the
growth of microvessel with ground substance, but also
can not affect the growth of tumor cells and the infiltra-
tion of cell factor and drugs. The results of vascularization
of alginate implants demonstrated that Msurvivin T34A
plasmid treated mice had a decrease of new vessels com-
pared with control groups, which conformed to the results
of FITC-dextran uptake of beads. (P < 0.05) (Figure 8)
Experiment of cytotoxicity T lymphocytes
In order to investigate whether Msurvivin T34A plasmid
could induce specific cellular immune response, we made
use of Cr51 release assay to examine primed T cells to
assess the cytotoxicity activity. Msurvivin T34A plasmid
treated group showed higher killing activity against autol-
ogous tumor cells, while T cells from the control group
failed to show any significant killing activity.(P <
0.05)(Figure 9A)
Toxicity assays
As the survivin can be expressed in adult normal tissue
such as hematopoietic progenitor cells, basal colonic epi-
thelial cells etc. and as a systematic therapic method
against tumors, injection through tail vein may lead to the
occurrence of systematic toxicity, we attempted to meas-
ure the toxicity of the treatment. Blood test did not show
obvious differences among three groups. The acute toxic
reaction of liver were evaluated by measuring the levels of
Representative DNA fluorescence histograms of PI-stained cells Figure 2
Representative DNA fluorescence histograms of PI-stained cells. 4T1 cells were treated with Msurvivin T34A plas-
mid(2 μg per well)for 48 hr.(a)untreated,(b)treated with PORF-9 null plasmid,(c)treated with Msurvivin T34A plasmid, with(a) 
2%,(b)8.6% and(d) 43% sub-G1 cells(apoptotic cells), respectively, as assessed by flow cytometry.Journal of Experimental & Clinical Cancer Research 2008, 27:46 http://www.jeccr.com/content/27/1/46
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Anti-tumor effects of Msurvivin T34A plasmid:lipo complexes versus normal saline, PORF-9 null plasmid:lipo complexes Figure 3
Anti-tumor effects of Msurvivin T34A plasmid:lipo complexes versus normal saline, PORF-9 null plasmid:lipo 
complexes. The tumor-bearing mice in each group received the corresponding treatment as detailed in "Materials and Meth-
ods". Data were presented as means ± SE. Each group contained 10 mice.(A) Tumor volume was shown up to 38. The differ-
ences between Msurvivin T34A plasmid:lipo and control groups were significant (P < 0.05) starting day 27.(B)Tumor weight 
was measured after each mice from every group was sacrificed. Compared with control groups, the Msurvivin T34A plasmid 
treated mice showed significant difference. (P < 0.01)Journal of Experimental & Clinical Cancer Research 2008, 27:46 http://www.jeccr.com/content/27/1/46
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serum AST and ALT of KM mice 48 h after receiving corre-
sponding treatments as described above. NO significant
differences between Msurvivin T34A plasmid treated
group and the control mice were found. (P > 0.05) (data
not shown). Body weights of mice were measured by a
digital balance every 3 or 4 days. The weight curve of each
group paralleled very closely. (data not shown) No gross
abnormalities were observed in the Msurvivin T34A plas-
mid treated group. Furthermore, no toxic pathologic
changes in heart, liver, spleen, lung and kidney were
detected by two pathologists among the three groups.
Discussion
As the most vital attribute of malignant tumor, metastases
have been a continuing therapeutic challenge, due to the
limited therapeutic effects of the modalities available
now. With regard to breast cancer, the most common
malignancy affecting women throughout the world,
numerous data suggest that when metastases occur, it
always means poor prognosis despite further treatment
such as surgery, radiotherapy, endocrinotherapy or tradi-
tional chemotherapy, though they have some curative
effects on breast cancer, especially in its early stages. In a
word, there is an imperative need to develop more effec-
tive agents to deal with combat metastatic breast cancer
better. One such approach is gene therapy.
Among the regulators of apoptosis that may participate in
cancer, survivin has attracted increasing attention because
of its essential role that is implicated in all kinds of cancer
survival, diagnosis and cancer treatment [4-6]. As a sup-
pressor of apoptosis, survivin is strongly expressed in the
most common human neoplasms [7-11], has prognostic
relevance for most cancers[15]and appears to be involved
in the response of tumor cells to chemotherapy and radi-
ation [12-14]. Furthermore, the expression of survivin in
normal adult tissues can not be detected or significantly
lower than in transformed cells[7]. So it is not difficult to
understand why survivin targeted treatment can not lead
to systemic toxicity. It has been reported that down-regu-
lation of survivin expression or function could reduce
tumor growth potential, increase the apoptotic rate and
sensitize tumor to chemotherapy and radiation in differ-
ent tumor models [16-20]. Mouse survivin T34A is a
phosphorylation-defective Thr34→Ala dominant nega-
tive mutant. Grossman et al. first demonstrated that trans-
fection of YUSAC2 and LOX melanoma cell lines with a
mutant carrying a cysteine 84→alanine mutation in the
Table 1: Lung metastatic nodules of each group
Groups Median no. of metastases (range)/lung % metastasis-free animals
Normal saline 35 (22–45) 0
PORF-9 null plasmid:lipo complexes 31.5 (19–46) 0
Msurvivin T34A plasmid:lipo complexes 5 (0–9)* 40*
*significantly (P < 0.05) differs from the control groups according to Mann-Whitney test
The anti-metastases effect of Msurvivin T34A plasmid:lipo complexes Figure 4
The anti-metastases effect of Msurvivin T34A plasmid:lipo complexes. (a) NS group, (b) PORF-9 null plasmid group, 
(c) Msurvivin T34A plasmid group. Compared with Msurvivin T34A plasmid group, a large number of lung metastatic nodules 
and structural destruction of pulmonary alveoli can be observed in NS and PORF-9 null plasmid group.Journal of Experimental & Clinical Cancer Research 2008, 27:46 http://www.jeccr.com/content/27/1/46
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survivin baculovirus IAP repeat domain increased the
apoptotic index and enhanced the sub-G1 apoptotic cell
fraction in both tumor models. Later, Grossman et al.
demonstrated the induction of spontaneous apoptosis in
different melanoma cell lines as well as an increased
apoptotic response following cisplatin treatment by using
a phosphorylationdefective survivin threonine
34→alanine mutant [21]. The mechanisms by which the
Msurvivin T34A induces apoptosis are mitochondrial-
dependent apoptosis with release of cytochrome c and
loss of mitochondrial transmembrane potential by target-
ing caspase 9 and other molecules [4]. Here, for the first
time, we evaluated the therapeutic efficacy of Msurvivin
T34A plasmid:lipo complexes on mouse metastatic breast
cancer 4T1 by intravenous injection and found the Msur-
vivin T34A plasmid had potent anti-tumor and anti-
metastases activity against mouse metastatic breast cancer
model in vitro and in vivo by triggering apoptosis of cancer
cells, inhibiting angiogenesis and inducing specific cellu-
lar immune response without obvious systemic toxicity.
The novel and efficient gene delivery system that we uti-
lized in present study is cationic liposome which increases
the therapeutic efficacy of Msurvivin T34A plasmid but
does not contribute to obvious systemic toxicity. As a non-
viral gene delivery system, Cationic liposome has low
immunogenicity, minimal toxicity. It has several advan-
tages. Firstly, among various formulations of cationic
liposome, it has been reported that DOTAP:Chol can
achieve higher levels of expression in all kinds of organs
Inhibition of intratumoral angiogenesis assayed by CD31 staining of microvessel Figure 5
Inhibition of intratumoral angiogenesis assayed by CD31 staining of microvessel. Vascularization within tumors was 
detected by an antibody to CD 31 and vascular density was quantified by counting the number of microvessel per high power 
field (×400). (A) Shown are representative sections from each group. (a)NS group, (b) PORF-9 null plasmid group, (c) Msur-
vivin T34A plasmid group. The arrows point to the necrosis. (b) CD31 positive microvessel in each group. Values were 
expressed as means ± SE (5 high power fields/slide).Journal of Experimental & Clinical Cancer Research 2008, 27:46 http://www.jeccr.com/content/27/1/46
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via tail vein injection in mice, compared with other for-
mulations such as DDAB:Chol, DDAB:DOPE and so on.
Secondly, DOTAP:Chol can provide more effective protec-
tion and delivery of DNA in circulation compared with
other formulations, partly because of its more cohesive
bilayer and its ability to effectively internalize DNA[23].
Lastly, intravenous injection of DOTAP:Chol-DNA com-
plexes in vivo can induce significantly increased uptake of
DOTAP:Chol-DNA complexes by tumor cells and ang-
iogenic endothelial cells in tumors than by normal cells
[31,32]. Moreover, previous studies showed that
DOTAP:Chol-DNA complexes could target lung, which
could protect lung from invasion of tumor cells [33,34].
All the evidences demonstrate cationic liposome
(DOTAP:Chol) is an ideal gene delivery system in our
study.
Before the in vivo test, we had made several studies con-
cerning the effect of Msurvivin T34A plasmid on 4T1 cells
in vitro. PI staining fluorescence microscopy and flow
cytometric analysis of Msurvivin T34A plasmid treated
tumor cells were conducted. The results of our findings
were consistent with the apoptosis-inducing ability of
Msurvivin T34A reported before [21]. These data suggest
that Msurvivin T34A plasmid can induce the apoptosis of
tumor cells directly.
In vivo test, we tested the Msurvivin T34A plasmid:lipo
complexes on mouse metastatic breast cancer 4T1 model.
We found that Msurvivin T34A plasmid efficiently inhib-
ited the growth of 4T1 cancer. The treatment with Msur-
vivin T34A plasmid resulted in primary tumor growth
regression of 73% and 57%, respectively, compared with
NS and PORF-9 null plasmid groups(P < 0.05). From the
results of examination of lungs, we found that the Msur-
vivin T34A plasmid treated mice had obvious reduction of
tumor nodules on the lungs compared with control
Terminal deoxynucleotidyltransferase-mediated dUTP nick- end labeling staining of tumor tissues Figure 6
Terminal deoxynucleotidyltransferase-mediated 
dUTP nick-end labeling staining of tumor tissues. Sec-
tions after treatment were stained by TUNEL analysis to 
detect apoptotic cells. Percent apoptosis was determined by 
counting the number of apoptotic cells and dividing by the 
total number of cells in the field (5 high power fields/slide). 
(A) Representative Field from each group. (a) NS group, (b) 
PORF-9 null plasmid group, (c) Msurvivin T34A plasmid 
group. (B) Percent apoptosis in each group. Values were 
expressed as means ± SE. Msurvivin T34A plasmid:lipo com-
plexes increased the percent apoptosis in breast tumor sec-
tions relative to either normal saline or PORF-9 null 
plasmid:lipo complexes. (p < 0.05, respectively).
Msurvivin T34A plasmid induced apoptosis of murine endothelial (MS1) cells in vitro Figure 7
Msurvivin T34A plasmid induced apoptosis of murine endothelial (MS1) cells in vitro. MS1 cells were treated with 
Msurvivin T34A plasmid(2 μg per well)for 48 hr.(a)untreated,(b)treated with PORF-9 null plasmid,(c)treated with Msurvivin 
T34A plasmid, with(a) 6.9%,(b) 18.9%and(d) 76.1% sub-G1 cells(apoptotic cells), respectively, as assessed by flow cytometry.Journal of Experimental & Clinical Cancer Research 2008, 27:46 http://www.jeccr.com/content/27/1/46
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groups. To our delight, 4 of 10 mice had no visible lung
metastases in the group treated with Msurvivin T34A plas-
mid. The results of H&E staining of lungs conformed to
the visible observation. These results indicate that Msur-
vivin T34A plasmid has a potent ability to stimulate anti-
tumor and anti-metastases activity in these mice with
established 4T1 breast tumor.
Having witnessed the profound anti-tumor and anti-
metastases activity of Msurvivin T34A plasmid in vitro and
in vivo, we did TUNEL staining of each group to evaluate
the anti-tumor mechanism in vivo. Our finding was also
consistent with the apoptosis-inducing ability of Msur-
vivin T34A plasmid mentioned above [21].
We also observed that Msurvivin T34A plasmid could
inhibit angiogenesis of tumor. Generation of blood ves-
sels plays a crucial role in the growth and progression of
most solid cancers[35,36]. It can influence the outcome of
chemotherapy to inhibit angiogenesis[37]. Targeting
tumor vasculature has been a new therapeutic strategy. It
is reported that the tumor cells supported by the vessel
would undergo apoptosis when endothelial cell apoptosis
is induced [38]. In this study, Msurvivin T34A plasmid
could induce obvious apoptosis of murine endothelial
cells (MS1) in vitro, CD31 staining of Msurvivin T34A
plasmid treated group showed the decrease of the number
of intratumoral microvessel in vivo and alginate-encapsu-
lated tumor cells test also confirmed that Msurvivin T34A
plasmid could indeed affect angiogenesis. Furthermore,
specific cytotoxic T cells can attack endothelial cell of
Vascularization of alginate implants Figure 8
Vascularization of alginate implants. (A) Representative alginate beads from each group.(a)NS group,(b)PORF-9 plasmid 
null plasmid group,(c)Msurvivin T34A plasmid group.(B) FITC-dextran uptake of beads from Msurvivin T34A plasmid treated 
mice showed a significant decrease compared with control groups(P < 0.05). The data were expressed as means ± S.E.Journal of Experimental & Clinical Cancer Research 2008, 27:46 http://www.jeccr.com/content/27/1/46
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tumor vessels, because the survivin is strongly expressed
in tumor endothelial cell.
Previous studies also showed that lymphocytes in human
tumor microenvironments are cytotoxic to the tumor cells
by in situ observations of lymphocyte-tumor cell interac-
tion[39,40]. Thus, active specific immunotherapies with
cancer vaccine-based tumor antigens represent very prom-
ising approaches for cancer therapy[41,42]. The success of
cancer immunotherapy is dependent on using suitable
tumor-associated antigens. Survivin is an ideal tumor-
associated antigen, for it is strongly expressed in most
solid tumors but poorly expressed in adult normal tissues
and it is obligatory for the survival of tumor cells. It is con-
ceivable that tumors may not be able to escape an anti-
survivin CTL response. Moreover, using Msurvivin T34A
plasmid as a vaccine can eliminate the potentially serious
problem of delivering a potent antiapoptotic activity asso-
ciated with wild type survivin. In current study, we uti-
lized Msurvivin T34A plasmid to produce specific
cytotoxic T lymphocyte response, which can target to rec-
ognize and attack the tumor cells.
Conclusion
Taken together, we demonstrate that the mouse survivin
T34A plasmid complexed with cationic liposome can effi-
ciently inhibit the growth and metastases of mouse highly
metastatic mammary carcinoma in vitro and in vivo. The
mechanism is involved in three aspects: triggering the
apoptosis of tumor cells, inhibiting angiogenesis and
inducing humoral and cellular immune response. Our
findings collectively suggest that Msurvivin T34A plasmid
can be considered as a new treatment approach for breast
cancer.
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